Best Peptides for Weight Loss 2026: A Research Guide

Weight research has changed more in the last two years than in the twenty before. A one-receptor drug that once defined the field now sits at the bottom of the ladder, passed by molecules that switch on two or three hormone receptors at once. So the question for a lab is no longer "which one is best" but "which mechanism fits the model". This guide ranks the five compounds that lead 2026 research by published trial results. It is for research and laboratory use only.

Key Takeaways

• Ranked by published trial results: retatrutide first, then tirzepatide and the cagrilintide pairing (CagriSema), then semaglutide. AOD-9604 is a different kind of compound, a fragment of growth hormone.
• Retatrutide (three receptors: GLP-1, GIP, glucagon) cut body weight by 25.0% at 80 weeks in the Phase 3 TRIUMPH-1 trial, and by 28.3% in people who stayed on the top dose. No other compound has matched it.
• Tirzepatide (two receptors: GLP-1, GIP) reached about 20 to 21%. Semaglutide (one receptor: GLP-1) reached about 15%, with the deepest research record.
• Cagrilintide is a long-acting amylin analog (half-life 159 to 195 hours). Paired with semaglutide as CagriSema, it reached 20.4%. AOD-9604 is a growth hormone fragment studied for fat breakdown without raising IGF-1.
• Mechanism, not marketing, separates these compounds, and every Lyze Labs batch ships with a published third-party HPLC COA verifying 99%+ purity.

Why the GLP-1 Era Redefined Weight Loss Peptide Research

It started with one gut hormone. GLP-1 (glucagon-like peptide-1) signals fullness and slows how fast the stomach empties, and semaglutide was the first copy of it to produce large, repeatable weight loss. Researchers then asked the obvious question: if one receptor works, what happens with two or three?

The answer was a clear ladder. In their main trials, semaglutide (one receptor) cut about 15% of body weight, tirzepatide (two) about 21%, and retatrutide (three) 25% and more. This is the "next-gen GLP-1 era".

For the three main agonists side by side, see the retatrutide vs tirzepatide vs semaglutide comparison.

Retatrutide: The Triple Agonist Setting the Ceiling

Retatrutide is the compound everyone in metabolic research is watching in 2026. It is the first molecule to switch on three hormone receptors at once: GLP-1, GIP and glucagon. The glucagon part is what sets it apart, because it raises the energy the body burns on top of the appetite effects the other two share.

The numbers are why it leads. In the Phase 3 TRIUMPH-1 trial (2,339 adults without diabetes), the 12 mg dose cut body weight by 25.0% at 80 weeks, against 3.9% on placebo; among people who stayed on treatment it was 28.3% (Jastreboff, 2026). TRIUMPH-4, in people with knee osteoarthritis, reported 28.7% at 68 weeks. Lilly plans to file for FDA approval in early 2027.

For researchers, that potency is exactly the appeal and exactly why purity matters so much. You can study the full dose-response profile of Retatrutide at our product page, where every lot is backed by HPLC verification.

Tirzepatide: The Dual-Agonist Benchmark

Tirzepatide switches on the GLP-1 and GIP receptors and became the benchmark for the field. In SURMOUNT-1, its top dose cut 20.9% of body weight at 72 weeks (Jastreboff, 2022). In the head-to-head SURMOUNT-5 trial it cut 20.2% against 13.7% for semaglutide, about 47% more (Aronne, 2025). That margin made two receptors the new floor.

GIP (glucose-dependent insulinotropic polypeptide) seems to add to the GLP-1 signal, though exactly how much it adds is still being studied. For labs comparing one receptor against two, tirzepatide is the cleanest reference; see the tirzepatide vs semaglutide comparison and the tirzepatide kit.

Semaglutide: The Most-Studied Single Agonist

Semaglutide should not be written off because newer compounds cut more weight. It has the most Phase 3 evidence and the longest follow-up of any compound here, which makes it the baseline every newer candidate is measured against. In STEP 1 it cut 14.9% of body weight at 68 weeks (Wilding, 2021), and the SELECT trial showed fewer heart attacks, strokes and heart deaths.

Its mechanism is the simplest of the group, which also makes it the easiest to isolate in an experiment. See the semaglutide kit.

Cagrilintide: The Amylin Analog Changing the Equation

Cagrilintide (AM833) is the wildcard because it works through a different receptor family. It is a long-acting amylin analog: a 37-amino-acid peptide (about 4409 Da, CAS 1415456-99-3) with a fatty acid attached, which switches on the amylin receptors and the calcitonin receptor in the brain's appetite centers.

Its standout property is how long it lasts: a half-life of 159 to 195 hours, so studies give it once a week. Because amylin is a separate pathway from the gut hormones, cagrilintide is most interesting next to a GLP-1 drug. Paired with semaglutide as CagriSema, it cut 20.4% of body weight at 68 weeks (Garvey, 2025). See the cagrilintide guide, the cagrilintide kit and the cagrilintide and semaglutide blend.

AOD-9604: The Targeted Lipolytic Fragment

AOD-9604 is here for contrast, because it is not a gut-hormone or amylin compound at all. It is a modified piece of human growth hormone, amino acids 176 to 191 with one tyrosine added. This 16-amino-acid section is the part of growth hormone tied to fat breakdown, and it is studied for fat metabolism without raising IGF-1 or blood sugar.

In obese rats, it more than halved weight gain over 19 days, raised fat breakdown and did not harm insulin sensitivity (Ng, 2000). Later human trials did not show large weight loss, so AOD-9604 is best seen as a tool for studying fat breakdown, not a high-impact weight compound. See the AOD-9604 kit and the related HGH Fragment 176-191 guide.

Best Peptides for Weight Loss 2026: Side-by-Side Comparison

These figures come from published trials and are for laboratory and research use only. They are not dosing guidance.

How to Choose, and Why Purity Decides the Outcome

For a study, the choice follows the mechanism: retatrutide for the largest effects, tirzepatide for the established benchmark, semaglutide for the deepest baseline, cagrilintide for a non-gut-hormone pathway, and AOD-9604 for fat-breakdown questions. Also worth a look for metabolic models: tesamorelin for belly fat and growth hormone, and SLU-PP-332 for exercise-like signals.

Whatever the choice, the variable that quietly ruins metabolic research is impurity. A peptide that is 90% pure brings 10% unknowns into your data. This is the single biggest reason to verify before you buy, a topic we cover in depth in our research peptide purity and COA verification guide and our research peptide scam red flags guide.

Every Lyze Labs compound is third-party HPLC tested at 99%+ purity, with a published COA tied to the specific batch you receive, so verification is built in rather than promised. Researchers in 150+ countries order from us, with 10,000+ orders shipped. Each kit is ten vials from one batch, and the more kits in an order, the lower the price of each.

Frequently Asked Questions

What are the best peptides for weight loss in 2026?

Ranked by published trial results: retatrutide (three receptors), then tirzepatide and the cagrilintide-semaglutide pairing, then semaglutide, with AOD-9604 as a fat-breakdown fragment. Each works through a different pathway, so the best choice depends on the mechanism your study needs. All are supplied for laboratory and research use only.

Which weight loss peptide shows the strongest research results?

Retatrutide. In the Phase 3 TRIUMPH-1 trial, it cut body weight by 25.0% at 80 weeks, and by 28.3% in people who stayed on the top dose. By switching on GLP-1, GIP and glucagon receptors, it sits above tirzepatide and semaglutide in every comparison so far.

How is Retatrutide different from Tirzepatide and Semaglutide?

Retatrutide switches on three receptors (GLP-1, GIP and glucagon), tirzepatide two (GLP-1 and GIP), and semaglutide one (GLP-1). Retatrutide's glucagon part raises the energy the body burns, which research links to its larger effect.

What is Cagrilintide and how does it work?

Cagrilintide is a long-acting amylin analog, a 37-amino-acid peptide that switches on amylin and calcitonin receptors in the brain to signal fullness. Its half-life is 159 to 195 hours, so studies give it once a week. Because it works through amylin rather than gut-hormone receptors, it is usually studied together with a GLP-1 drug.

Is AOD-9604 as effective as GLP-1 peptides for weight loss research?

No. AOD-9604 is a growth hormone fragment studied for fat breakdown without raising IGF-1 or blood sugar. Animal studies showed effects on fat metabolism, but human trials did not reproduce the large weight losses seen with GLP-1 drugs. It is best seen as a specialist tool for fat-breakdown research.

How do I verify the purity of weight loss research peptides?

Always require a batch-specific third-party HPLC certificate of analysis (COA) confirming 99%+ purity before purchase. Lyze Labs publishes a COA for every lot, so you can match the document to the exact vial you receive. Our purity verification guide explains how to read an HPLC report and spot the red flags of low-quality or mislabeled material.

Order the Next-Gen Weight Loss Research Peptides

Browse retatrutide and the full GLP-1 and metabolic range, then order in minutes. A person confirms your order and sends payment options, day or night: card, PayPal, Apple Pay, Google Pay, bank transfer, local wallets or crypto. Free discreet worldwide shipping arrives in 7 to 14 days, every order backed by a published HPLC COA, with 10,000+ orders shipped to researchers in 150+ countries.

Studies Cited

• Jastreboff AM, et al. (2026). Retatrutide, a triple hormone receptor agonist, for treatment of obesity. New England Journal of Medicine.
• Jastreboff AM, et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine.
• Aronne LJ, et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine.
• Wilding JPH, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine.
• Garvey WT, et al. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine.
• Ng FM, et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research.